Day 2 Conference: Gilead News & FDA Response
JPM24 Day 2: Key Takeaways from Biotech’s Biggest Week
Table of Contents
The J.P. Morgan Healthcare Conference continued on January 9, 2024, with ongoing discussions and announcements shaping the biotech landscape. This report summarizes key developments from the second day of the conference.
Notable Presentations and Announcements
- Eli Lilly and Company CEO David Ricks presented positive data for the company’s weight-loss drug,Mounjaro (tirzepatide),and discussed plans for a potential new manufacturing facility in Indiana,representing an investment of over $2.8 billion, according to a company press release.
- novo Nordisk executives highlighted the strong demand for Wegovy (semaglutide), their weight-loss drug, and outlined strategies to address supply constraints.
- Moderna shared updated data on its mRNA-based cancer vaccine, mRNA-4157/v940, in combination with pembrolizumab, demonstrating a 44% reduction in the risk of disease recurrence or death in a Phase 3 trial, as reported by STAT News.
- BioNTech announced a collaboration with Pfizer to develop a new mRNA-based vaccine for influenza, aiming to begin human trials in 2024, according to a BioNTech press release.
Venture Capital Trends
Venture capital funding in the biotech sector remains cautious, but several companies secured significant investments. According to data presented at JPM24, total venture funding for biotech in 2023 reached $23.8 billion, a 48% decrease from the $45.6 billion raised in 2021, as reported by STAT News.
Key Themes Emerging at JPM24
Artificial intelligence (AI) continues to be a dominant theme, with numerous companies showcasing AI-powered drug discovery platforms and data analytics tools. The focus on obesity and diabetes treatments remains strong, driven by the success of drugs like Mounjaro and Wegovy.
The J.P. Morgan Healthcare Conference continues through January 11,2024. Further updates will be provided as they become available.